SNDX FY 2024 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$24M

Gross Profit

$23M96.5% margin

Operating Income

-$340M-1434.4% margin

Net Income

-$319M-1346.1% margin

EPS (Diluted)

$-3.73

Cash Flow

Operating Cash Flow

-$275M

Free Cash Flow

-$275M

Stock-Based Comp.

$43M

Balance Sheet

Total Assets

$725M

Total Liabilities

$437M

Stockholders' Equity

$288M

Cash & Equivalents

$154M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$24M	$0	—
Gross Profit	$23M	$0	—
Operating Income	-$340M	-$230M	-47.7%
Net Income	-$319M	-$209M	-52.3%